The University of Alberta was ranked sixth globally for academic impact transplantation in 2016, and leads nationally and internationally in research, clinical and facilities.
The Division of Transplantation has been a leader in clinical trials of antirejection therapies in solid organ transplant and in the genomics of transplantation. Accomplishments have included developing the antirejection drug, rapamycin, for immunosuppression in liver transplant patients with hepatocellular carcinoma. The division also leads efforts to develop improved criteria for selecting appropriate patients with hepatocellular carcinoma for liver transplantation, as well as in development and evaluation of therapy for hepatitis C and B.
The cardiothoracic transplant group is a leader in the development of ex-vivo perfusion systems. The islet transplant program continues to be the world’s busiest and a leader in pushing the frontiers of tissue engineering.
The division offers transplantation clinical services in kidneys, heart, lung, liver, simultaneous kidney pancreas and whole pancreas, small intestine, visceral and islet transplantation. It runs the second-largest liver and lung transplant program in the country and performs the second-highest cumulative number of transplants annually in Canada. All heart, lung, liver, intestine and islet transplants in Alberta are performed at the University of Alberta Hospital (UAH), the Mazankowski Alberta Heart Institute and the Stollery Children’s Hospital, which have state-of-the-art surgical equipment, including brand new and hybrid operating rooms.
Facilities and Technology
The division has access to world-class facilities and institutions including: the Ray Rajotte Surgical Medical Research Institute (See photo), Alberta Diabetes Institute and the Li Ka Shing Centre for Health Research Innovation.
Alberta Transplant Institute
The university’s Alberta Transplant Institute (ATI) brings together clinicians, researchers, educators, and policy-makers entirely dedicated to advancing transplantation in Canada. The ATI impacts all levels of the healthcare system, supporting clinical transplant care and moving cutting-edge research into improved patient outcomes.
The ATI’s director is Dr. Lori West, the Canada Research Chair in Cardiac Transplantation (Tier 1). She is the Director of the Canadian National Transplant Research Program, and a Professor in the Departments of Pediatrics, Surgery, and Medical Microbiology & Immunology.
The Director of the Division of Transplantation is Dr. Norman Kneteman, Professor of Surgery and Zone Clinical Section Chief of Transplants at the UAH and for AHS. He heads the Alberta Liver Transplant Program and started the first liver transplant program in Western Canada at the UAH.